Cytokinetics, Incorporated (CYTK)
NasdaqGS · USD · Healthcare · Biotechnology
$60.73 (-0.82%) as of
Key statistics
- Market cap
- 8.44B
- Forward P/E
- -13.80
- EPS (TTM)
- -7.22
- Dividend yield
- 0.00%
- 52-week range
- 58.05 – 88.31
- Beta
- 0.41
- Revenue (TTM)
- 67.67M
- Profit margin
- 0.00%
- Analyst target
- $109.20
- Volume
- 783.22k
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA, United States
- Employees
- 673
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.